Cargando…

COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?

High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvestris, N., Di Maio, M., Russo, A., Chiari, R., De Giorgi, U., Del Mastro, L., Giuffrida, D., La Verde, N., Perrone, F., Tucci, M., Beretta, G.D., Cinieri, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973080/
https://www.ncbi.nlm.nih.gov/pubmed/33819751
http://dx.doi.org/10.1016/j.esmoop.2021.100100
_version_ 1783666771746619392
author Silvestris, N.
Di Maio, M.
Russo, A.
Chiari, R.
De Giorgi, U.
Del Mastro, L.
Giuffrida, D.
La Verde, N.
Perrone, F.
Tucci, M.
Beretta, G.D.
Cinieri, S.
author_facet Silvestris, N.
Di Maio, M.
Russo, A.
Chiari, R.
De Giorgi, U.
Del Mastro, L.
Giuffrida, D.
La Verde, N.
Perrone, F.
Tucci, M.
Beretta, G.D.
Cinieri, S.
author_sort Silvestris, N.
collection PubMed
description High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients’ needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: ‘how can we deal with COVID-19 infection in cancer patients?’ In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health care professionals and institutions in the decision-making processes the pandemic has engendered within this scenario. The relevant documents as well as the educational and institutional initiatives the AIOM has taken are reported in this article.
format Online
Article
Text
id pubmed-7973080
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-79730802021-03-19 COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave? Silvestris, N. Di Maio, M. Russo, A. Chiari, R. De Giorgi, U. Del Mastro, L. Giuffrida, D. La Verde, N. Perrone, F. Tucci, M. Beretta, G.D. Cinieri, S. ESMO Open Review High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients’ needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: ‘how can we deal with COVID-19 infection in cancer patients?’ In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health care professionals and institutions in the decision-making processes the pandemic has engendered within this scenario. The relevant documents as well as the educational and institutional initiatives the AIOM has taken are reported in this article. Elsevier 2021-03-19 /pmc/articles/PMC7973080/ /pubmed/33819751 http://dx.doi.org/10.1016/j.esmoop.2021.100100 Text en © 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Silvestris, N.
Di Maio, M.
Russo, A.
Chiari, R.
De Giorgi, U.
Del Mastro, L.
Giuffrida, D.
La Verde, N.
Perrone, F.
Tucci, M.
Beretta, G.D.
Cinieri, S.
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
title COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
title_full COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
title_fullStr COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
title_full_unstemmed COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
title_short COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
title_sort covid-19 infection in cancer patients: what has been the contribution of associazione italiana oncologia medica (aiom) to oncological care since the beginning of the first pandemic wave?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973080/
https://www.ncbi.nlm.nih.gov/pubmed/33819751
http://dx.doi.org/10.1016/j.esmoop.2021.100100
work_keys_str_mv AT silvestrisn covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT dimaiom covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT russoa covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT chiarir covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT degiorgiu covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT delmastrol covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT giuffridad covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT laverden covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT perronef covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT tuccim covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT berettagd covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave
AT cinieris covid19infectionincancerpatientswhathasbeenthecontributionofassociazioneitalianaoncologiamedicaaiomtooncologicalcaresincethebeginningofthefirstpandemicwave